Company Encyclopedia
View More
name
Intellia Therap
NTLA.US
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc.
1.946 T
NTLA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking104/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-52.11%E
    • Profit Margin-774.94%E
    • Gross Margin-472.84%E
  • Growth ScoreB
    • Revenue YoY33.52%A
    • Net Profit YoY14.64%C
    • Total Assets YoY-21.14%E
    • Net Assets YoY-22.25%E
  • Cash ScoreB
    • Cash Flow Margin-12.90%D
    • OCF YoY33.52%A
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreA
    • Gearing Ratio19.11%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Intellia Therapeutics, Inc. $NTLA Shares Sold by Orchard Capital Management LLC

    Orchard Capital Management LLC reduced its stake in Intellia Therapeutics by 57.3% in Q2, selling 106,288 shares. Intellia's stock is now its 29th largest position, comprising 0.8% of its holdings. Other institutional investors have adjusted their positions in NTLA. Intellia's stock opened at $8.52, with a market cap of $986.87 million. Analysts have mixed ratings, with a consensus target price of $18.43. Intellia's Q3 revenue rose 51.6% year-over-year, with EPS beating estimates.

    Market Beat·
    US
    NTLA
    +7.51%
    Market Beat·
    US
    NTLA
    +7.51%

    Intellia Therapeutics (NTLA): Evaluating the Stock’s Value After a Steep 35% Monthly Decline

    Intellia Therapeutics (NTLA) has seen a 35% decline in its stock price over the past month, prompting a reevaluation of its valuation and future prospects. Despite trading near record lows, the stock is considered undervalued with a fair value estimated above $22. However, safety concerns and regulatory scrutiny pose risks. The company trades at a high price-to-sales ratio, raising overvaluation concerns. Investors are encouraged to explore broader market opportunities and consider potential risks and rewards before investing.

    Simplywall·
    US
    NTLA
    +7.51%
    Simplywall·
    US
    NTLA
    +7.51%

    Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Hold" from Analysts

    Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average "Hold" rating from 24 brokerages. Analysts have varied opinions, with some recommending sell, hold, or buy. The stock's target price averages $18.43. Recent insider trading and institutional investments have influenced stock ownership. The company reported better-than-expected quarterly earnings, with revenue up 51.6% year-over-year. Intellia focuses on genome editing therapeutics, with several programs in clinical trials.

    Market Beat·
    US
    NTLA
    +7.51%
    Market Beat·
    US
    NTLA
    +7.51%

    17:31 ET KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight

    DelveInsight's report forecasts significant growth in the KLKB1 inhibitors market by 2034, driven by novel therapies targeting inflammatory, cardiovascular, and rare diseases. Key players like Intellia Therapeutics and Astria Therapeutics are advancing clinical trials for new inhibitors. The market is expanding beyond hereditary angioedema to include diabetic macular edema and other conditions, aligning with trends in personalized medicine and drug development advancements.

    prnewswire·
    US
    ATXS
    +0.23%
    US
    NTLA
    +7.51%
    prnewswire·
    US
    ATXS
    +0.23%
    US
    NTLA
    +7.51%

    Intellia Therapeutics Reports Q3 2025 Financial Results

    Intellia Therapeutics Inc reported Q3 2025 financial results, highlighting a cash position of $670 million, collaboration revenue of $13.8 million, and a net loss of $101.3 million. The company is addressing FDA clinical hold issues in its MAGNITUDE trials and advancing its lonvo-z program. Intellia anticipates regulatory submissions and potential commercial launches in the coming years.

    Tip Ranks·
    US
    NTLA
    +7.51%
    Tip Ranks·
    US
    NTLA
    +7.51%
    © 2025 Longbridge｜Disclaimer